Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: Enhancement of effect by batimastat

European Journal of Cancer Part A

Volumn 33, Issue 7, 1997, Pages 1114-1121

  Burke, F ^a   East, N ^b   Upton, C ^c   Patel, K ^d   Balkwill, F R ^a  

^a Biological Therapy Laboratory   (United Kingdom)

^b Clare Hall Laboratories ^*  (United Kingdom)

^c Electron Microscopy   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Animal model; Apoptosis; Batimastat; IFN ; Ovarian cancer

Indexed keywords

BATIMASTAT; CARBOPLATIN; METALLOPROTEINASE INHIBITOR; RECOMBINANT GAMMA INTERFERON;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DIAGNOSIS; DNA SYNTHESIS; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; IMMUNOREGULATION; MOUSE; OVARY CANCER; PRIORITY JOURNAL;

EID: 0030855863     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)88065-3     Document Type: Article

References (36)

1. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993, 11, 571-611.
2. Takikawa O, Kuroiwa T, Yamazaki F, Kido R. Mechanism of interferon γ action. J Biol Chem 1988, 263, 2041-2048.
3. Ozaki Y, Edelstein M, Duch D. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumour activity of interferon γ. Proc Natl Acad Sci USA 1988, 85, 1242-1246.
4. Fen GS, Taylor MW. Interferon gamma resistant mutants are defective in the induction of indoleamine dioxygenase. Proc Natl Acad Sci USA 1989, 86, 7144-7148.
5. Leung BS, Stout LE, Shaskan EG, Thompson RM. Differential induction of indoleamine-2-3 dioxygenase (IDO) by interferon-γ in human gynecologic cancer cells. Cancer Lett 1992, 66, 77-81.
6. Jett JR, Maksymiuk AW, Su JQ, et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 1994, 12, 2321-2326.
7. Aulitzky WE, Lerche J, Thews A, et al. Low-dose gamma-interferon therapy is ineffective in renal-cell carcinoma patients with large tumour burden. Eur J Cancer 1994, 30A, 940-945.
8. Aulitzky WE, Aulitzky W, Gastle G, et al. Acute effects of single doses of recombinant interferon-γ on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. J Interferon Res 1989, 9, 425-433.
9. Pujade-Lauraine E, Guastalla J-P, Colombo N, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996, 14, 343-350.
10. Malik STA, Knowles RG, East N, Lando D, Stamp G, Balkwill FR. Antitumour activity of gamma interferon in ascitic and solid tumour models of human ovarian cancer. Cancer Res 1991, 51, 6643-9.
11. Arends MJ, Morris RG, Wyllie AH. Apoptosis. The role of the endonuclease. Am J Pathol 1990, 136, 593-608.
12. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980, 68, 251-306.
13. Iigo M, Shimizu I, Sagawa K. Synergistic antitumour effects of carboplatin and interferons on hepatic metastases of colon carcinoma 26 and M5076 reticulum cell sarcoma. Jpn J Cancer Res 1993, 84, 794-799.
14. Marth C, Helmberg M, Mayer I, Fuith LC, Daxenbichler G, Dapunt O. Effects of biological response modifiers on ovarian carcinoma cell lines. Anticancer Res 1989, 9, 461-467.
15. Nehme A, Albin N, Caliaro MJ, et al. Mechanism of interaction between cisplatin and human recombinant interferon-gamma in human ovarian-cancer cell-lines. Int J Cancer 1995, 61, 643-648.
16. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts [Published erratum appears in Cancer Res 1993. Aug 1, 53 (15), 3652]. Cancer Res 1993, 53, 2087-2091.
17. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts [Published erratum appears in Cancer Res 1993. Aug 1, 53 (15), 3652]. Cancer Res 1993, 53, 2087-2091.
18. Chirivi RGS, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994, 58, 406-464.
19. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994, 54, 4726-4728.
20. Balkwill FR, Lee A, Aldam G, et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 1986, 46, 3990-3993.
21. Ward BG, Wallace K, Sheperd JH, Balkwill FR. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res 1987, 47, 2662-2667.
22. Malik STA, Griffin DB, Fiers W, Balkwill FR. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer 1989, 44, 918-925.
23. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. New York, Cold Spring Harbor Press, 1989.
24. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76, 4350-4354.
25. Gavrieli Y, Sherman Y, Ben Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992, 119, 493-501.
26. Freireich EJ, Gehan EA, Rail DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1996, 50, 219-44.
27. Elbendary A, Berchuck A, Davis P, et al. Transforming growth factor beta 1 can induce C1P1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 1994, 5, 1301-1307.
28. Jeoung DI, Tang BQ, Sonenberg M. Induction of tumor-suppressor p21 protein by kinase inhibitors in mcf-7 cells. Biochem Biophys Res Commun 1995, 214, 361-366.
29. Burke F, Refl M, Negus R, Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 1996, 8, 578-585.
30. Vedantham S, Gamliel H, Golomb HM. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res 1992, 52, 1056-1066.
31. Brown PD. Clinical trials of a low molecular weight matrix metalloproteinase inhibitor in cancer. Ann NY Acad Sci 1994, 732, 217-221.
32. Granstein RD, Murphy GF, Margolis RJ, Byrne MH, Amento EP. Gamma-interferon inhibits collagen synthesis in vivo in the mouse. J Clin Invest 1987, 79, 1254-1258.
33. Kahari VM, Heino J, Vuorio T, Vuorio E. Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochim Biophys Acta 1988, 968, 45-50.
34. Taraboletti G, Garofalo A, Belotti D, et al. Inhibition of angio-genesis and murine hemangioma growth by Batimatstat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995, 87, 293-298.
35. Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994, 370, 555-557.
36. Balkwill FR, Ward BG, Moodie E, Fiers W. Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer. Cancer Res 1987, 47, 4755-4758.